MONTREAL, QUEBEC--(MARKET WIRE)--Sep 11, 2007 -- Theratechnologies (Toronto:TH.TO - News) announced today that it has learned from the US Food and Drug Administration (FDA) that, based on the information known today, the tesamorelin (TH9507) clinical development program is moving in the right direction.
